Results 221 to 230 of about 116,711 (370)
A case of a non–small‐cell lung cancer patient harboring epidermal growth factor receptor mutation with multiple brain metastasis experienced a new ischemic stroke after treatment with ramucirumab. Abstract Vascular endothelial growth factor (VEGF) inhibitors have been widely investigated in the last 10 years, with particular attention paid to their ...
Guo‐Yu Chen+2 more
wiley +1 more source
Epidermolysis bullosa for primary care providers: A practical review
Abstract Epidermolysis bullosa (EB) is a group of genetic skin diseases, which manifest as fragile skin and blistering in addition to many extracutaneous conditions. Pediatricians and primary care providers play an integral role in managing these patients with multifaceted care needs.
Kennedy Sparling+9 more
wiley +1 more source
Patients with T790M‐negative EGFR‐mutant advanced NSCLC received anlotinib plus platinum‐based chemotherapy after resistance to first‐ or second‐generation EGFR TKIs. The maximum tolerated dose (MTD) of anlotinib was 12 mg, and the median PFS was 5.75 (95% CI: 4.37–7.52) months.
Juan Li+7 more
wiley +1 more source
An Evaluation of the Incidence of and the Maternal Disability following Eclampsia and Albuminuria [PDF]
James Young+2 more
openalex +1 more source
An Inquiry into Certain Points Connected with Albuminuria [PDF]
R. Saundby
openalex +1 more source
The efficacy of PDE5 inhibitors in diabetic patients
Abstract Background Phosphodiesterase 5 inhibitors (PDE5i), since their introduction in the late 1990s, have proven their efficacy in treating several conditions, predominantly pulmonary hypertension and erectile dysfunction where they remain the first‐line therapeutic option.
Agnieszka Swiecicka
wiley +1 more source